Figure S1 - Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
Domaine:
healthcareType de record:
dataset
Créateur:
JosThoSteGra
Hôte:
Full Markov Model. Full Markov model showing the four cryptococcal prevention strategies - 1) no screening or prophylaxis (standard of care or status quo), 2) universal primary prophylaxis with fluconazole 200mg daily, 3) CRAG screening with high-dose fluconazole treatment for all patients testing positive (800mg fluconazole daily for two weeks, followed by 400mg daily for eight weeks, then 200mg daily maintenance) and 4) CRAG screening with lumbar puncture for all patients testing positive, amphotericin-B 1mg/kg/day for two weeks for those with CNS disease and fluconazole 800mg daily for two weeks for those without, in both cases followed by fluconazole 400mg daily for eight weeks, then 200mg daily maintenance as above.
(TIF)
Similaires
Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in BotswanaEvaluation of the Initial 12 Months of a Routine Cryptococcal Antigen Screening Program in Reduction of HIV-Associated Cryptococcal Meningitis in UgandaHIV–associated Cryptococcal MeningitisCost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South AfricaAdjunctive dexamethasone in HIV-associated cryptococcal meningitisCryptococcal antigen titers and semi-quantitative assay scores among people with HIV-associated cryptococcal antigenemia